261 related articles for article (PubMed ID: 29278207)
1. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
Nanasi P; Komaromi I; Gaburjakova M; Almassy J
Curr Med Chem; 2018; 25(15):1720-1728. PubMed ID: 29278207
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of a myosin motor activator agent with increased selectivity.
Nánási P; Komáromi I; Almássy J
Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
[TBL] [Abstract][Full Text] [Related]
3. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
4. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
5. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle.
Nánási P; Gaburjakova M; Gaburjakova J; Almássy J
Eur J Pharmacol; 2017 Aug; 809():73-79. PubMed ID: 28506910
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
Mack M; Frishman WH
Cardiol Rev; 2024 Jul-Aug 01; 32(4):378-383. PubMed ID: 36946979
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
[TBL] [Abstract][Full Text] [Related]
8. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
[TBL] [Abstract][Full Text] [Related]
10. Response to Letter Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity".
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Nov; 8(6):1142. PubMed ID: 26738203
[No Abstract] [Full Text] [Related]
11. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity".
Teerlink JR; Malik FI; Kass DA
Circ Heart Fail; 2015 Nov; 8(6):1141. PubMed ID: 26578671
[No Abstract] [Full Text] [Related]
12. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
Shen YT; Malik FI; Zhao X; Depre C; Dhar SK; Abarzúa P; Morgans DJ; Vatner SF
Circ Heart Fail; 2010 Jul; 3(4):522-7. PubMed ID: 20498236
[TBL] [Abstract][Full Text] [Related]
13. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
[TBL] [Abstract][Full Text] [Related]
15. The myosin activator omecamtiv mecarbil: a promising new inotropic agent.
Nánási P; Váczi K; Papp Z
Can J Physiol Pharmacol; 2016 Oct; 94(10):1033-1039. PubMed ID: 27322915
[TBL] [Abstract][Full Text] [Related]
16. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?
Moin DS; Sackheim J; Hamo CE; Butler J
Curr Cardiol Rep; 2016 Oct; 18(10):100. PubMed ID: 27568794
[TBL] [Abstract][Full Text] [Related]
18. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.
Mamidi R; Gresham KS; Li A; dos Remedios CG; Stelzer JE
J Mol Cell Cardiol; 2015 Aug; 85():262-72. PubMed ID: 26100051
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
